Background:
Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating
people with both HIV and NHL.
Objective:
To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL.
Eligibility:
Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features.
Design:
Individuals will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of individual s tumors. In some cases, a new biopsy may be needed.
Individuals will receive up to 6 cycles of treatment.
The first cycle is 26 days: Individuals will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All individuals will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete.
The remaining cycles are each 21 days. Individuals will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle.
Screening tests will be repeated at study visits.
Follow-up visits will continue for 4 years....
Leptomeningeal/CSF involvement
High-risk for CNS relapse per CNS-IPI (score 4-6)
Plasmablastic histology
Gamma herpesvirus positive tumor
Individuals may not receive investigational agents on other clinical trials.
Requirement of any of the agents listed as prohibited thearapies.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide or other agents used in study.
Parenchymal brain involvement with lymphoma.